LOS ANGELES, CA / ACCESSWIRE / May 31, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against PPG Industries, Inc. (”PPG” or ”the Company”) (NYSE: PPG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between April 24, 2017 and May 10, 2018, inclusive (the ”Class Period”), are encouraged to contact the firm before July 19, 2018.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, PPG made false and misleading statements to the marketplace. It states that the Company’s consolidated financial statements for the year ending December 31, 2017, and the quarterly statements of 2017 all contained improper accounting entries and could not be relied upon by the investing public. PPG also failed to sustain appropriate internal controls. As a result, the Company’s financial statements were materially false and misleading throughout the class period and did not accurately reflect the results of business operations and the financial health of PPG. According to the lawsuit, when accurate information about PPG became apparent in the market, investors suffered damages.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
Sherin Mahdavian, Esq.,
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 501434

PORT VILA, VANUATU / ACCESSWIRE / May 31, 2018 / The strong performance of all the world’s major economies in early 2018 has given rise to the term “synchronous growth,” as countries continue to recover from the 2008 financial crisis. Genesys Fund notes that clients are paying increasing attention to developments beyond the US to maximize value in their investments. Although international markets comprise 60% of global public capital markets, the typical US investor’s portfolio only contains around 21% international equity and bonds, according to CNBC.

Reuters has reported that recent volatility in the US stock market has created incentives for fund managers to consider re-allocating capital to international bonds and emerging market stocks. Financial analysts have warned of a potential mismatch between fiscal and monetary policy, as the Trump administration attempts to stimulate the economy by implementing $1.5 trillion in tax cuts while the Federal Reserve considers raising interest rates to dampen borrowing. International markets can act as a balance to developments in the US, allowing fund managers to spread the risk over a diversified portfolio when domestic and global economies do not move in the same direction.

Another reason that investors are taking their money abroad is simply the impressive performance reported for some non-US companies. For example, the FAANG stocks, comprised of US corporations Facebook, Amazon, Alphabet, Netflix, and Google (with Microsoft added in occasionally) are usually coveted by investors. However, the rise of Chinese technology firms termed the BATs – Baidu, Alibaba Group and Tencent – have challenged the unquestioned appeal of FAANGs. In mid-2017, the BATs posted a 65% growth, compared to 31% growth for the US-based grouping.

Prospects of healthy growth in the global economy will also create more options for US investors when deciding where to send their capital. The International Monetary Fund expects that global economic growth will average 3.9% in 2018 and 2019, after a stronger than expected 2017. The uptick in commodity demand from emerging economies is a key indicator of industrial recovery. Although these economies have lagged the US in expansion in recent years, their long term outlook remains positive. Growing populations translate into increased demand for goods and services, while economic expansion will lead to a rise in demand for metals, minerals and crude oil. Growth in Asia alone is forecast to average 6.5% in 2018 and 2019, accounting for over 50% of the world total. The savvy investor will also integrate currency risk management into their international investment strategy, says Genesys Fund, since the depreciation of foreign currencies against the US dollar will erode profits gained from the international markets.

An investment hedge fund founded in 2016, Genesys Fund works with institutional and private investors in 82 countries, providing clients with multi-asset execution, prime brokerage services and modern trading technology. The firm manages a diversified portfolio comprised of financial products for options, futures, bond and forex trading. By creating proprietary analytical and accounting systems for risk control, the fund delivers a world-class investment offering to clients.

GenesysFund – The Most Robust Asset Management Offerings Available: http://www.genesysfundnews.com

Genesys Fund – Explores the Growing Government Interest in Cryptocurrencies: https://finance.yahoo.com/news/genesys-fund-explores-growing-government-014000146.html

Genesys Fund on How Innovative Technologies Drive Impact Investing: https://finance.yahoo.com/news/genesys-fund-innovative-technologies-drive-181000178.html

Contact Information:

GenesysFundNews.com
contact@genesysfundnews.com
http://www.genesysfundnews.com

SOURCE: GenesysFundNews.com

ReleaseID: 501410

LOS ANGELES, CA / ACCESSWIRE / May 31, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Micro Focus International plc (”Micro Focus” or ”the Company”) (NYSE: MFGP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s American Depository Shares pursuant and/or traceable to the registration statement and prospectus (the “Registration Statement”) issued in connection with the merger of Micro Focus and Hewlett Packard Enterprise Company (“HPE”), which closed on September 1, 2017 (“the Merger”), are encouraged to contact the firm before July 23, 2018.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, Micro Focus made false and misleading statements to the marketplace. It alleges that the Company failed to disclose that HPE was experiencing significant and global customer account disruptions due to its de-merger with Hewlett Packard. HPE and Micro Focus were also suffering from employee attrition, which negatively impacted Micro Focus’s revenue trend and operational abilities. Micro Focus’s revenue trends were worsening and on pace to miss expectations in the market for its interim results reported for the six months ending on October 31, 2017. The Company was also suffering from sales execution problems in North America. HPE did not have key assets like a loyal customer base, key personnel, or operational capabilities to justify its purchase price. Micro Focus failed to put in place the necessary operations, staff, and plan to effectively integrate with HPE in order to increase the chances of enjoying a positive synergy between the two organizations. According to the complaint, the total enterprise value of the merger was allegedly inflated by more $3.4 billion. As a result of these points, Micro Focus’s ability to service the debt load it took on as part of the Merger was materially impaired. The lawsuit states that when the market learned the true facts of Micro Focus and the Merger, investors suffered damages.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
Sherin Mahdavian, Esq.,
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 501433

NEW YORK, NY / ACCESSWIRE / May 31, 2018 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Telefonaktiebolaget LM Ericsson (“Ericsson”) (NASDAQ: ERIC) securities between April 8, 2013 and July 17, 2017.

Click here to learn about the case: http://www.wongesq.com/pslra-c/telefonaktiebolaget-lm-ericsson?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Ericsson prematurely recognized revenues and improperly delayed the recognition of costs related to services contracts; and (2) as a result of the foregoing, Ericsson materially overstated its revenues, margins, and profits during the Class Period. On July 18, 2017, Ericsson reported disappointing results for the second quarter ended June 30, 2017 and announced that it had identified 42 contracts to be transformed, exited or renegotiated. On this news, shares of Ericsson fell from a close of $7.28 per share on July 17, 2017, to a close of $6.07 per share on July 18, 2017.

If you suffered a loss in Ericsson you have until June 5, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/telefonaktiebolaget-lm-ericsson?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 501429

NEW YORK, NY / ACCESSWIRE / May 31, 2018 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Synacor, Inc. (“Synacor”) (NASDAQ: SYNC) securities between May 4, 2016, and March 15, 2018.

Click here to learn about the case: http://www.wongesq.com/pslra-c/synacor-inc?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Synacor was unlikely to receive significant revenues from its contract with AT&T until 2018; (ii) as such, the Company’s revenue forecasts issued during the Class Period were materially false and misleading; and (iii) as a result of the foregoing, Synacor shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.

If you suffered a loss in Synacor you have until June 4, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/synacor-inc?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway Suite 304
New York, NY 10002
Tel. 212.425.1140
Tax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 501428

SAN DIEGO, CA / ACCESSWIRE / May 31, 2018 / Emerald Health Pharmaceuticals Inc. (EHP), which is developing medicines based on cannabinoid science, will be featured as a presenting company at the upcoming LD Micro Invitational to be held on June 4-6, 2018 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Jill Broadfoot, Chief Financial Officer of EHP, will provide a corporate overview on Monday, June 4, 2018 at 2:00 PM PT/ 5:00 PM ET and will be available to meet with investors. If you would like to attend the Company’s presentation or schedule a meeting, please click on the following link: https://www.ldmicro.com/events.

This conference will feature 230 companies in the small-cap / micro-cap space, and will be attended by over 1,000 individuals.

About Emerald Health Pharmaceuticals Inc.

Emerald Health Pharmaceuticals is developing product candidates derived from cannabinoids for the treatment of CNS, autoimmune, and other diseases. The company has two families of new chemical entities, based on cannabidiol, CBD, and cannabigerol, CBG, that it has modified through rational drug design to affect validated receptors pertinent to targeted diseases. Its first drug candidate, EHP-101, is focused on treating multiple sclerosis and scleroderma. Its second, EHP-102, is focused on treating Huntington’s disease and Parkinson’s disease. The company is advancing preclinical development with the intent to launch a Phase 1 clinical study in 2018. For more information, visit www.emeraldpharma.life or contact: info@emeraldpharma.life.

Forward-Looking Statements

To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered “forward-looking statements,” as described in the Private Securities Litigation Reform Act of 1995, that reflect management’s current beliefs and expectations. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “hope,” “hypothesis,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “will,” “would,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this news release include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; and (iv) our ability to raise capital. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals’ investigational drug products have not been approved or cleared by the FDA.

CONTACT:

Investor Relations
Phone: (800) 268-0719

SOURCE: Emerald Health Pharmaceuticals Inc.

ReleaseID: 501424

LOS ANGELES, CA / ACCESSWIRE / May 31, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rockwell Medical, Inc. (“Rockwell Medical” or the “Company”) (NASDAQ: RMTI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On May 22, 2018, Rockwell Medical announced that effective immediately, the President and Chief Executive Officer of the company, Robert Chioini, had been terminated. On May 23, 2018, a letter to shareholders on behalf of Mr. Chioini was published outlining an emergency board meeting called by Mr. Chioini for the purpose of discussing a shareholder demand letter alleging breaches of fiduciary duties and other possible violations of securities laws by Rockwell Medical directors. The shareholder demand letter also stated that the directors whose conduct and actions were the subject of alleged breaches of fiduciary duties asserted that they voted to terminate Mr. Chioini. The letter to shareholders added that Mr. Chioini “continues to serve as the CEO consistent with the terms of his employment agreement.” On May 24, 2018, trading in Rockwell Medical shares was halted.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 501425

LOS ANGELES, CA / ACCESSWIRE / May 31, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Telefonaktiebolaget LM Ericsson (“the Company”) (ERIC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between April 8, 2013 and June 17, 2017, inclusive (the “Class Period”), are encouraged to contact the firm before June 5, 2018.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: 1) Ericsson prematurely recognized revenues and improperly delayed the recognition of costs related to services contracts; and (2) as a result, Ericsson materially overstated its revenues, margins, and profits during the Class Period. When the truth was revealed to the investing public, shares dropped, causing shareholders harm.

The Schall Law Firm represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
Sherin Mahdavian, Esq.,
Schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 501422

LOS ANGELES, CA / ACCESSWIRE / May 31, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against TrueCar, Inc. (”the Company”) (NASDAQ: TRUE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between February 16, 2017 and November 6, 2017, inclusive (the ”Class Period”) are encouraged to contact the firm before June 1, 2018.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: (1) the largest source of TrueCar’s revenue, the United States Automobile Association (”USAA”), had been planning significant changes to its website that would have a material adverse effect on the volume of purchases generated by USAA; (2) USAA made significant changes to its website that would have a material adverse effect on the volume of purchases generated by USAA; (3) the changes to USAA’s website maintained by TrueCar caused a material adverse effect on the volume of purchases generated by USAA; and (4) as a result, defendants’ statements about TrueCar’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis. When the truth was revealed to the investing public, shares dropped, causing shareholders harm.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.
Schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 501421